Abstracts tagged "Spondyloarthropathies"

Abstract Number: 0575 • ACR Convergence 2024
Combined Testing of anti-CD74 IgA and Anti-UH-axSpA Antibodies Increases the Diagnostic Potential for axSpA
Kurt de Vlam¹, Pieter Ruytinx², Elien luyten², Anouk Agten², Frank Vandenabeele² and Veerle somers², ¹Department of Rheumatology, UZ Leuven, and Department of Development and Regeneration, Skeletal Biology and Engineering Research Center, KU Leuven, Leuven, Belgium, ²Universiteit Hasselt, Hasselt, Belgium
Background/Purpose: Diagnosis of axial spondyloarthritis (axSpA) is challenging and a specific laboratory diagnostic test is lacking. Previously, we identified novel immunoglobulin G (IgG) and IgA…
Abstract Number: 1482 • ACR Convergence 2024
Predictors of Clinical Response to Intravenous Secukinumab Among Patients with Axial Spondyloarthritis: A Post Hoc Analysis of a Phase 3 Trial
Atul Deodhar¹, Eva Dokoupilova², Cynthia Vizcaya³, Reema Sutariya⁴, Weibin Bao⁴, Karen Kapur³, Susanne Rohrer³ and Alan Kivitz⁵, ¹Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, ²Medical Plus, s.r.o., Uherske Hradiste, and Masaryk University, Faculty of Pharmacy, Department of Pharmaceutical Technology, Prague, Czech Republic, ³Novartis Pharma AG, Basel, Switzerland, ⁴Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁵Altoona Center for Clinical Research, Duncansville, PA

Background/Purpose: This post hoc analysis of the INVIGORATE-1 study evaluated potential predictors of Ankylosing Spondylitis international Society (ASAS) 40 response in patients with axial spondyloarthritis…
Abstract Number: 0078 • ACR Convergence 2024
Inhibition of the Deubiquitinase TRABID in a Pre-clinical Mouse Model of Axial Spondyloarthritis Decreases Disease Severity
Archita Srinath¹, Daniele Mauro², Mariia Korshko³, Shaghayegh Foroozan⁴, Mansi Aparnathi⁵, Francesco Ciccia⁶ and Nigil Haroon⁷, ¹University of Toronto, Toronto, ON, Canada, ²University of Campania, Italy, Naples, Naples, Italy, ³University Health Network, Toronto, ON, Canada, ⁴University Health Network/University of Toronto, Toronto, ON, Canada, ⁵University Health Network, Toronto, Canada, ⁶University of Campania, Naples, Italy, ⁷Department of Medicine/Rheumatology, University Health Network, Schroeder Arthritis Institute, University of Toronto, Toronto, ON, Canada
Background/Purpose: Axial Spondyloarthritis is characterized by both inflammation and new bone formation. Current therapeutic targets aim to control inflammation, however, over 40% of patients do…
Abstract Number: 0589 • ACR Convergence 2024
Time to Clinical Response to Secukinumab Across Disease Domains Among Patients with Psoriatic Arthritis: A Pooled Post Hoc Analysis of 4 Phase 3 Trials
Laura Coates¹, Iain McInnes², M. Elaine Husni³, Cynthia Vizcaya⁴, Weibin Bao⁵ and Philip Mease⁶, ¹University of Oxford, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom, ²University of Glasgow, College of Medical Veterinary and Life Sciences, Glasgow, United Kingdom, ³Cleveland Clinic, Cleveland, OH, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁶Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA
Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory disease that can manifest with considerable clinical heterogeneity. Secukinumab demonstrated improvements across the updated Group for Research and…
Abstract Number: 1707 • ACR Convergence 2024
TRBV9-Targeted Bispecific T Cell-Engaging Antibodies to Reset the Autoreactive T Cell Compartment in Spondyloarthritis and HLA-DQ8 Celiac Disease
Stephanie Glavaris, Alexander Pearlman, Jin Liu, Jiaxin Ge, Yuanxuan Xia, Kyle J. Kaeo, Tolulope Awosika, Colin Gliech, Tushar Nichakawade, Nikita Marcou, Chetan Bettegowda, Drew Pardoll, Kenneth W. Kinzler, Shibin Zhou, Bert Vogelstein, Suman Paul and Maximilian F. Konig, The Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Therapies that indiscriminately deplete all T cells carry a high risk of opportunistic infection, precluding their widespread use in T cell-mediated autoimmune diseases. Targeting…
Abstract Number: 0082 • ACR Convergence 2024
Comparative Immunology of Entheseal Anchorage Sites Between Spine, Hip and Knee Demonstrates up to 70-fold Greater IL-23 Induction from Axial Enthesis Bone: A New Angle on the Failure of IL-23 Blockade in Ankylosing Spondylitis
Mark Harland¹, Paula David², Chi Wong¹, Jake Weddell¹, Abhay Rao³, Almas Khan³, Jake Timothy³, Peter Loughenbury³, Robert Dunsmuir³, Vishal Borse³, Campbell MacEachern³, Antonius Pieter Van der Heuvel⁴, Warner Chen⁴, Tom Macleod¹ and Dennis McGonagle⁵, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), University of Leeds, Leeds, UK, Leeds, United Kingdom, ²Department of Medicine B, Sheba Medical Center, Tel Hashomer, Israel, Ramat Gan, Israel, ³Leeds Teaching Hospitals NHS Trust, Leeds, UK, Leeds, United Kingdom, ⁴Janssen Research & Development, LLC, a Johnson & Johnson Company, Spring House, PA, USA, Spring House, PA, ⁵National Institute for Health Research (NIHR) Leeds Biomedical Research Centre (BRC), Leeds Teaching Hospitals, Leeds, UK, Leeds, England, United Kingdom
Background/Purpose: Both peripheral and axial spondyloarthropathy (SpA), psoriasis and inflammatory bowel disease are strongly linked to IL-23 pathway immunogenetics and immunology. Unexpectedly, IL-23 inhibition lacked…
Abstract Number: 0590 • ACR Convergence 2024
Efficacy of Secukinumab Across the Axial Spondyloarthritis Spectrum Among Patients Grouped by Age (≥40 Years vs < 40): A PostHoc Analysis of 6 Phase 3 Trials
Sofia Ramiro¹, Corine Gaillez², Uta Kiltz³, Lianne S Gensler⁴, Chaitali Pisal⁵, Juergen Braun⁶ and Alexis Ogdie⁷, ¹Leiden University Medical Center, Bunde, Netherlands, ²Novartis Pharma AG, Basel, Switzerland, ³Rheumazentrum Ruhrgebiet Herne, Ruhr-University, D-44649 Herne, Germany, ⁴Department of Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁵Novartis Healthcare Private Limited, Hyderabad, India, ⁶Rheuma Praxis, Ruhr-University Bochum, Berlin, Germany, ⁷Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: Secukinumab is an IL-17 inhibitor approved to treat axial spondyloarthritis (axSpA), including radiographic (r)-axSpA and non-radiographic (nr)-axSpA. Recent ASAS-EULAR recommendations highlight the importance of…
Abstract Number: 1760 • ACR Convergence 2024
A Phase 2 Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of a Mitogen-activated Protein Kinase-Activated Protein Kinase 2 (MK2) Inhibitor in Active Ankylosing Spondylitis
Walter Maksymowych¹, Robert Lambert¹, Paula Śliwinska-Stańczyk², Piotr Adrian Klimiuk³, Anusha Yeshokumar⁴, Elizabeth Cerullo⁴, Rebecca Kepich⁴, Chahin Pachai⁴ and Steven Greenberg⁴, ¹University of Alberta, Edmonton, AB, Canada, ²Centrum Medyczne ReumaPark, Warsaw, Poland, ³Medical University of Bialystok and Inter Clinic Piotr Adrian Klimiuk, Department of Rheumatology and Internal Diseases, Białystok, Poland, ⁴Bristol Myers Squibb, Princeton, NJ
Background/Purpose: CC-99677 (also known as BMS-986371) is a novel, orally bioavailable, small-molecule covalent inhibitor of mitogen-activated protein (MAP) kinase-activated protein kinase 2 (MK2). The MK2…
Abstract Number: 0141 • ACR Convergence 2024
The Effect of Systemic Immunosuppressive Therapies on Cardiovascular Risk in Psoriatic Arthritis Patients
Melody Esmaeili¹, Linh Truong², Nicole Ridolfi³, Eugenia Chen⁴ and Maida wong⁵, ¹University of California, Irvine, Orange, CA, ²University of California, Los Angeles, Los Angeles, CA, ³University of California, Irvine, Newport Beach, CA, ⁴Long Beach VA Hospital, Irvine, CA, ⁵Long Beach VA Hospital, Los Angeles, CA
Background/Purpose: Evidence demonstrates an increased prevalence of atherosclerotic cardiovascular disease (ASCVD) among psoriatic arthritis (PsA) patients. However, the relationship between immunosuppressive therapies and the development of ASCVD remains unclear.…
Abstract Number: 0604 • ACR Convergence 2024
Secular Trends in Biologic Prescribing for Psoriasis and Psoriatic Arthritis, 2014-2024
Mahum Mirza¹, Jean Liew², Michael Putman³ and Shikha Singla¹, ¹Medical College of Wisconsin, Milwaukee, WI, ²Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ³The Medical College of Wisconsin, Milwaukee, WI
Background/Purpose: Treatment options for psoriasis or psoriatic arthritis (PsA) have expanded in the past decade. Secular trends in biologic disease modifying antirheumatic drug (bDMARD) prescribing…
Abstract Number: 1850 • ACR Convergence 2024
Exhausted T-cells Are Increased in Autoimmune Diseases and Predict Response to Anti-TNF in RA and SPA Patients
Samuel Bitoun¹, Marie Naigeon², Matthieu Roulleaux- Dugage², Caroline De Oliveira², Caroline Berthot², Xavier Mariette³, Gaetane Nocturne³ and Nathalie Chaput-Gras², ¹Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin-Bicetre, France, ²Laboratoire d'immunomonitoring en Oncologie, INSERM US23, CNRS UMS 3655, Gustave Roussy,, Villejuif, France, ³Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin Bicetre, France
Background/Purpose: Exhaustion can occur after prolonged activation of T cells limiting their immunosurveillance function leading to cancer emergence. Among the exhaustion markers expressed on T…
Abstract Number: 0230 • ACR Convergence 2024
Spine and Sacroiliac Joint Involvement in Newly Diagnosed Patients with Inflammatory Bowel Disease – Clinical and MRI Findings from a Population-Based Cohort Study
Nora Vladimirova¹, Jakob Møller², Mohamed Attauabi², Gorm Madsen³, Lene Terslev⁴, Charlotte Wiell⁵, Viktoria Fana⁶, Sanja Bay Hansen³, Hartwig Siebner³, Jakob Seidelin², Flemming Bentsen³, Kasper Gosvig⁷, Johan Burisch³ and Mikkel Ostergaard⁸, ¹Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Righospitalet, Copenhagen, Denmark, ²Herlev and Gentofte Hospital, copenhagen, Denmark, ³Hvidovre Hospital, copenhagen, Denmark, ⁴Rigshospitalet-Glostrup & COPECARE, Glostrup, Denmark, ⁵Rigshospitalet-Glostrup, Copenhagen, Denmark, ⁶Rigshospitalet-Glostrup, Glostrup, Denmark, ⁷Department of Radiology, Copenhagen University Hospital Herlev-Gentofte, Herlev, Denmark, ⁸Department of Clinical Medicine, University of Copenhagen and Center for Rheumatology, Copenhagen Center for Arthritis Research, Glostrup, Denmark
Background/Purpose: In patients with inflammatory bowel disease (IBD), coexistence of spondyloarthritis (SpA), the most common extraintestinal manifestation, is associated with poor outcomes and impaired quality…
Abstract Number: 0817 • ACR Convergence 2024
2024 Clinical Practice Guideline for the Diagnosis and Treatment of Chronic Nonbacterial Osteitis (CNO) in Adults
Elizabeth Winter, Olaf Dekkers and Anne Leerling, and the Expert Consensus Panel for Chronic Nonbacterial Osteitis (CNO) in Adults, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Adults with sterile bone inflammation are variably labelled as Synovitis, Acne, Pustulosis, Hyperostosis, Osteitis (SAPHO)-syndrome, chronic nonbacterial osteomyelitis, chronic recurrent multifocal osteomyelitis (CRMO), pustulotic…
Abstract Number: 1875 • ACR Convergence 2024
Assessing the PULSAR (Program to Understand the Longterm Outcomes in Spondyloarthritis) Registry for Environmental Determinants of Heath Research
Liya Stolyar¹, Diane Mar², Yuhan Liu³, Esther Velasquez⁴, orr Sharpe⁵, Michael Weisman⁶, Liron Caplan⁷ and suzanne Tamang⁸, ¹Palo Alto VA Medical Center/Stanford, Stanford, CA, ²Palo Alto VA Medical Center/Stanford University Medical Center, Palo Alto, CA, ³Stanford Medicine Quantitative Sciences Unit, Palo Alto, CA, ⁴Stanford Center for Population Health Sciences, Palo Alto, CA, ⁵Department of Immunology and Rheumatology, Stanford University, Stanford, CA, ⁶Stanford University, Los Angeles, CA, ⁷Univ of Colorado School of Medicine/Rocky Mtn Regional Veterans Affairs Medical Center, Aurora, CO, ⁸Stanford University, Atherton, CA
Background/Purpose: Acute exposure to air pollution has been associated with flares of psoriasis and chronic inflammatory arthritides in prior studies. However, the impact of air pollution,…
Abstract Number: 0234 • ACR Convergence 2024
MRI of Sacroiliac Joints: Is Contrast Necessary for the Detection of Sacroiliitis?
Damira Sereda¹, Arun Venkataraman¹, Harlan Stock¹ and Andras Perl², ¹SUNY Upstate Medical University, Syracuse, NY, ²SUNY, Syracuse, NY
Background/Purpose: Spondyloarthropathy (SpA) encompasses several conditions, such as ankylosing spondylitis, psoriatic arthritis, reactive arthritis, arthritis linked with inflammatory bowel disease, and undifferentiated spondyloarthritis [1]. Sacroiliitis…

1
2
3
…
11
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.